What is Travere Therapeutics Inc Annual Revenue?

Travere Therapeutics Inc Annual Revenue rose 60.55%, in the last year to $233.18 M. Its sector's average revenue growth for the last fiscal year was 7.48%.

What is Travere Therapeutics Inc Annual Net Profit?

Travere Therapeutics Inc Annual Net Profit fell 188.64% in the last year to $321.54 M. Its sector's average net profit growth for the last fiscal year was -32.59%.

What is Travere Therapeutics Inc Price to Earning Ratio?

Travere Therapeutics Inc Price to Earning Ratio is -4, which is negative.

What is Travere Therapeutics Inc Stock Price?

Travere Therapeutics Inc Stock Price rose 116.74% and outperformed its sector by 115.41% in the past year.

What is Travere Therapeutics Inc Quarterly Revenue?

Travere Therapeutics Inc Quarterly Revenue rose 65.98% YoY to $74.79 M. Its sector's average revenue growth YoY for the quarter was 5.86%.

What is Travere Therapeutics Inc Quarterly Net profit?

Travere Therapeutics Inc Quarterly Net profit rose 33.17% YoY to $60.26 M. Its sector's average net profit growth YoY for the quarter was -47.22%.

What is Travere Therapeutics Inc Debt to Equity Ratio?

Travere Therapeutics Inc Debt to Equity Ratio of 6.8 is higher than 1. This implies that company assets are financed through debt.

What is Travere Therapeutics Inc Return on Equity(ROE)?

Travere Therapeutics Inc Return on Equity(ROE) for the last financial year was -247.45%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Travere Therapeutics Inc Mutual Fund Holding?

Travere Therapeutics Inc Mutual Fund Holding increased by 1.04% in the last quarter to 60.96.

What is Travere Therapeutics Inc Promoter Share Holding?

Travere Therapeutics Inc Promoter Share Holding increased by 0.33% in the most recent quarter to 2.97%.

What is Travere Therapeutics Inc Interest Coverage Ratio?

Travere Therapeutics Inc Interest Coverage Ratio is -27.66, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Travere Therapeutics Inc Institutional Holding?

Travere Therapeutics Inc Institutional Holding remained the same in the last quarter at 106.73%.

How is the Travere Therapeutics Inc today?

The Travere Therapeutics Inc today is trading in the green, up by 7.49% at 14.50.

How has Travere Therapeutics Inc performed historically?

The Travere Therapeutics Inc is currently trading up 7.49% on an intraday basis in the past week the index fell -3.27%. The index has been down -19.85% in the past quarter and rose 116.74% in the past year. You can view this in the overview section.

Travere Therapeutics Inc XNAS: TVTX

Travere Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Name: Travere Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Travere Therapeutics Inc
Rating: 1.05066675
Author: Trendlyne DVM scores

Momentum Trap

Download real time

14.50 1.01 (7.49%)

42.67% Fall from 52W High

1.6M XNAS Volume

XNAS 11 Apr, 2025 5:30 PM (EDT)

Travere Therapeutics Inc Key Metrics

My Metrics

Select

Market Capitalization Below industry Median Unavailable in chosen country	1,287.2
PE TTM Negative PE TTM Unavailable in chosen country	-4
Price to Book High in industry Unavailable in chosen country	21.8
Institutional holding current Qtr % High in industry Unavailable in chosen country	106.7
Revenue Growth Qtr YoY % High in industry Unavailable in chosen country	66
Operating Revenue growth TTM % High in industry Unavailable in chosen country	60.5
Net Profit Qtr Growth YoY % Below industry Median Unavailable in chosen country	33.2
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-188.6
Operating Profit Margin Qtr % Negative Operating Profit Margin Qtr % Unavailable in chosen country	-79.3
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-137.8
Piotroski Score Below industry Median Unavailable in chosen country	2
Rel Perf vs Sector quarter% Unavailable in chosen country	-17.4
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-247.4
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-46.5

All financials are in USD Million and price data in USD

Low Financial Strength

16.7 / 100

Expensive Valuation

8.5 / 100

Technically Neutral

42.2 / 100

Momentum Trap These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM

1Yr Price target upside is 132%

15 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Travere Therapeutics Inc Stock Price Analysis

Day Price Range 7.5% 1 Day return Unavailable in chosen country	14.5 (LTP) 13.114.7 LowHigh
Week Price Range -3.3% 1 Week return Unavailable in chosen country	14.5 (LTP) 12.916 LowHigh
Month Price Range -20.0% 1 Month return Unavailable in chosen country	14.5 (LTP) 12.921.4 LowHigh
52 Week Price Range 116.7% 1 Year return Unavailable in chosen country	14.5 (LTP) 5.125.3 LowHigh

View full Share Price History

Travere Therapeutics Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Travere Therapeutics Inc's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-4.1

Avg. Estimate

-1.4

Low Estimate

-2.4

High Estimate

-0.6

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 65.4% in FY25

Consensus Recommendation

16 ANALYST Recommendations

STRONG BUY

The consensus recommendation from 16 analysts for Travere Therapeutics Inc is STRONG BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Travere Therapeutics Inc Stock Analysis

Travere Therapeutics Inc stock analysis with key metrics, changes, and trends.

Travere Therapeutics Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$233.18 M	60.55%	positive	Annual Revenue rose 60.55%, in the last year to $233.18 M. Its sector's average revenue growth for the last fiscal year was 7.48%.
Annual Net Profit	$321.54 M	188.64%	negative	Annual Net Profit fell 188.64% in the last year to $321.54 M. Its sector's average net profit growth for the last fiscal year was -32.59%.
Price to Earning Ratio	-4	-	negative	Price to Earning Ratio is -4, which is negative.
Stock Price	$14.50	116.74%	positive	Stock Price rose 116.74% and outperformed its sector by 115.41% in the past year.
Quarterly Revenue	$74.79 M	65.98%	positive	Quarterly Revenue rose 65.98% YoY to $74.79 M. Its sector's average revenue growth YoY for the quarter was 5.86%.
Quarterly Net profit	$60.26 M	33.17%	positive	Quarterly Net profit rose 33.17% YoY to $60.26 M. Its sector's average net profit growth YoY for the quarter was -47.22%.
Debt to Equity Ratio	6.8	-	negative	Debt to Equity Ratio of 6.8 is higher than 1. This implies that company assets are financed through debt.
Return on Equity(ROE)	-247.45 %	-247.45%	negative	Return on Equity(ROE) for the last financial year was -247.45%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	60.96 %	1.04%	positive	Mutual Fund Holding increased by 1.04% in the last quarter to 60.96.
Promoter Share Holding	2.97 %	0.33%	positive	Promoter Share Holding increased by 0.33% in the most recent quarter to 2.97%.
Interest Coverage Ratio	-27.66	-	negative	Interest Coverage Ratio is -27.66, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).
Institutional Holding	106.73 %	0%	neutral	Institutional Holding remained the same in the last quarter at 106.73%.

VIEW LESS

Loading data..

Travere Therapeutics Inc - Company Profile

What does Travere Therapeutics Inc do?

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.

2024

Gross Remuneration

Year

Travere Therapeutics Inc Live Share Price Today, Share Analysis and Chart

42.67% Fall from 52W High

Travere Therapeutics Inc Key Metrics

Market Capitalization

PE TTM

Price to Book

ROE Annual %

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

RoA Annual %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Travere Therapeutics Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Travere Therapeutics Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Travere Therapeutics Inc's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

EPS is expected to grow by 65.4% in FY25

Consensus Recommendation

The consensus recommendation from 16 analysts for Travere Therapeutics Inc is STRONG BUY

Travere Therapeutics Inc Stock Analysis

Travere Therapeutics Inc stock analysis with key metrics, changes, and trends.

Annual Revenue rose 60.55%, in the last year to $233.18 M. Its sector's average revenue growth for the last fiscal year was 7.48%.

Annual Net Profit fell 188.64% in the last year to $321.54 M. Its sector's average net profit growth for the last fiscal year was -32.59%.

Price to Earning Ratio is -4, which is negative.

Stock Price rose 116.74% and outperformed its sector by 115.41% in the past year.

Quarterly Revenue rose 65.98% YoY to $74.79 M. Its sector's average revenue growth YoY for the quarter was 5.86%.

Quarterly Net profit rose 33.17% YoY to $60.26 M. Its sector's average net profit growth YoY for the quarter was -47.22%.

Debt to Equity Ratio of 6.8 is higher than 1. This implies that company assets are financed through debt.

Return on Equity(ROE) for the last financial year was -247.45%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 1.04% in the last quarter to 60.96.

Promoter Share Holding increased by 0.33% in the most recent quarter to 2.97%.

Interest Coverage Ratio is -27.66, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding remained the same in the last quarter at 106.73%.

Travere Therapeutics Inc - Company Profile

What does Travere Therapeutics Inc do?

Travere Therapeutics Inc Management structure

Dr. Eric M. Dube, PhD

Director, President and Chief Executive Officer

Dr. Jula Inrig, M.D.

Chief Medical Officer

Dr. William E. Rote, PhD

Chief Research Officer

Mr. Peter Heerma

Chief Commercial Officer

Mr. Christopher Cline

Chief Financial Officer

Ms. Elizabeth E. Reed

Chief Legal Officer, General Counsel and Corporate Secretary

Travere Therapeutics Inc Board of directors

Mr. Gary A. Lyons

Chairman of the Board

Mr. Timothy P. Coughlin